Pasar al contenido principal

INGENIERIA METABOLICA DE ASHBYA GOSSYPII PARA LA PRODUCCION DE ACIDOS GRASOS UTILIZANDO RESIDUOS INDUSTRIALES

BIO2014-56930-P

•
Nombre agencia financiadora Ministerio de Economía y Competitividad
Acrónimo agencia financiadora MINECO
Programa Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D (Excelencia / Generación de Conocimiento)
Año convocatoria 2014
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Unidad de gestión Secretaría de Estado de Educación, Formación Profesional y Universidades
Centro beneficiario UNIVERSIDAD DE SALAMANCA
Identificador persistente http://dx.doi.org/10.13039/501100003329

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Guanine nucleotide binding to the Bateman domain mediates the allosteric inhibition of eukaryotic IMP dehydrogenases

  • Martínez Buey, Rubén
  • Ledesma Amaro, Rodrigo
  • Velázquez-Campoy, Adrián
  • Balsera, Mónica
  • Chagoyen, Mónica
  • Pereda, José M. de
  • Revuelta Doval, José Luis
This work is licensed under a Creative Commons Attribution 4.0 International License., Inosine-50-monophosphate dehydrogenase (IMPDH) plays key roles in purine nucleotide metabolism and cell proliferation. Although IMPDH is a widely studied therapeutic target, there is limited information about its physiological regulation. Using Ashbya gossypii as a model, we describe the molecular mechanism and the structural basis for the allosteric regulation of IMPDH by guanine nucleotides. We report that GTP and GDP bind to the regulatory Bateman domain, inducing octamers with compromised catalytic activity. Our data suggest that eukaryotic and prokaryotic IMPDHs might have developed different regulatory mechanisms, with GTP/GDP inhibiting only eukaryotic IMPDHs. Interestingly, mutations associated with human retinopathies map into the guanine nucleotide-binding sites including a previously undescribed non-canonical site and disrupt allosteric inhibition. Together, our results shed light on the mechanisms of the allosteric regulation of enzymes mediated by Bateman domains and provide a molecular basis for certain retinopathies, opening the door to new therapeutic approaches., This work was supported by grant BIO2014–56930-P (J.L.R.) and BFU2013-47064-P (A.V-.C.) from the Spanish Ministerio de Economía y Competitividad, grant B89/Protein Targets Group (A.V.-C.) from the Diputación General de Aragón and grant FP7-PEOPLE-2011-CIG-293831 (EB-SxIP; R.M.B.). R.M.B. is supported by a ‘Ramón y Cajal’ contract from the Spanish Ministerio de Economía y Competitividad. The research leading to these results has received funding from the European Community’s 7th Framework Programme (FP7/2007–2013) under BioStruct-X (grant agreement no 7687)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Mitochondria and lipid raft-located FOF1-ATP synthase as major therapeutic targets in the antileishmanial and anticancer activities of ether lipid edelfosine

  • Villa-Pulgarín, J. A.
  • Gajate, Consuelo
  • Botet, Javier
  • Jiménez, Alberto
  • Justies, Nicole
  • Varela-M, Rubén E.
  • Cuesta-Marbán, Álvaro
  • Müller, Ingrid
  • Modolell, Manuel
  • Revuelta Doval, José Luis
  • Mollinedo, Faustino
[Background]:Leishmaniasis is the world's second deadliest parasitic disease after malaria, and current treatment of the different forms of this disease is far from satisfactory. Alkylphospholipid analogs (APLs) are a family of anticancer drugs that show antileishmanial activity, including the first oral drug (miltefosine) for leishmaniasis and drugs in preclinical/clinical oncology trials, but their precise mechanism of action remains to be elucidated., [Methodology/Principal Findings]:Here we show that the tumor cell apoptosis-inducer edelfosine was the most effective APL, as compared to miltefosine, perifosine and erucylphosphocholine, in killing Leishmania spp. promastigotes and amastigotes as well as tumor cells, as assessed by DNA breakdown determined by flow cytometry. In studies using animal models, we found that orally-administered edelfosine showed a potent in vivo antileishmanial activity and diminished macrophage pro-inflammatory responses. Edelfosine was also able to kill Leishmania axenic amastigotes. Edelfosine was taken up by host macrophages and killed intracellular Leishmania amastigotes in infected macrophages. Edelfosine accumulated in tumor cell mitochondria and Leishmania kinetoplast-mitochondrion, and led to mitochondrial transmembrane potential disruption, and to the successive breakdown of parasite mitochondrial and nuclear DNA. Ectopic expression of Bcl-XL inhibited edelfosine-induced cell death in both Leishmania parasites and tumor cells. We found that the cytotoxic activity of edelfosine against Leishmania parasites and tumor cells was associated with a dramatic recruitment of FOF1-ATP synthase into lipid rafts following edelfosine treatment in both parasites and cancer cells. Raft disruption and specific FOF1-ATP synthase inhibition hindered edelfosine-induced cell death in both Leishmania parasites and tumor cells. Genetic deletion of FOF1-ATP synthase led to edelfosine drug resistance in Saccharomyces cerevisiae yeast., [Conclusions/Significance]:The present study shows that the antileishmanial and anticancer actions of edelfosine share some common signaling processes, with mitochondria and raft-located FOF1-ATP synthase being critical in the killing process, thus identifying novel druggable targets for the treatment of leishmaniasis., This work was supported by grants from the Spanish Ministerio de Economia y Competitividad (SAF2014-59716-R and BIO2014-56930-P), Instituto de Salud Carlos III (RD12/0036/0065 from Red TemaÂtica de Investigación Cooperativa en Cáncer, cofunded by the EU's European Regional Development Fund ± FEDER),European Community's Seventh Framework Programme FP7-2007-2013 (grant HEALTH-F2-2011-256986, PANACREAS), and Spain-UK International Joint Project grant from The Royal Society-CSIC (2004GB0032). CG was supported by the RamoÂn y Cajal Program from the Spanish Ministerio de Ciencia e Innovación.AÂCM was recipient of Formación de Profesorado Universitario predoctoral fellowship from the Spanish Ministerio de Ciencia e Innovación., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A nucleotide-controlled conformational switch modulates the activity of eukaryotic IMP dehydrogenases

  • Martínez Buey, Rubén
  • Fernández-Justel, David
  • Marcos-Alcalde, Íñigo
  • Winter, Graeme
  • Gómez-Puertas, Paulino
  • Pereda, José M. de
  • Revuelta Doval, José Luis
Inosine-5′-monophosphate dehydrogenase (IMPDH) is an essential enzyme for nucleotide metabolism and cell proliferation. Despite IMPDH is the target of drugs with antiviral, immunosuppressive and antitumor activities, its physiological mechanisms of regulation remain largely unknown. Using the enzyme from the industrial fungus Ashbya gossypii, we demonstrate that the binding of adenine and guanine nucleotides to the canonical nucleotide binding sites of the regulatory Bateman domain induces different enzyme conformations with significantly distinct catalytic activities. Thereby, the comparison of their high-resolution structures defines the mechanistic and structural details of a nucleotide-controlled conformational switch that allosterically modulates the catalytic activity of eukaryotic IMPDHs. Remarkably, retinopathy-associated mutations lie within the mechanical hinges of the conformational change, highlighting its physiological relevance. Our results expand the mechanistic repertoire of Bateman domains and pave the road to new approaches targeting IMPDHs., This work was supported by the Spanish Ministerio de Economía y Competitividad (grant BFU2016–79237-P to Rubén M Buey, contracts IPT2011-0964-900000 and SAF2011-13156-E to Paulino Gómez-Puertas, and grant BIO2014-56930-P to José Luis Revuelta). Rubén M Buey is supported by a “Ramón y Cajal” contract from the Spanish Ministerio de Economía y Competitividad. We thank María Dolores Sánchez and Silvia Domínguez for excellent technical help. Protein crystallography experiments were performed at the i03 beamline (Diamond Light Source, UK) and XALOC (ALBA Synchrotron, Spain) beamlines with the collaboration of Diamond and ALBA staff. X-ray scattering experiments were performed at the P12 beamline in Petra III synchrotron (Hamburg, Germany) with the collaboration of the P12 beamline staff. The research leading to these results has received funding from the European Community’s 7th Framework Program (FP7/2007–2013) under BioStruct-X (grant agreement number 7687)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A nucleotide-dependent conformational switch controls the polymerization of human IMP dehydrogenases to modulate their catalytic activity

  • Fernández-Justel, David
  • Núñez-Ramírez, Rafael
  • Martín-Benito, Jaime
  • Jimeno, David
  • González-López, Adrián
  • Soriano, Eva María
  • Revuelta Doval, José Luis
  • Martínez Buey, Rubén
36 p.-6 fig.+inf. supl.18 p.-8 fig.-2 tab., Inosine 5'-monophosphate dehydrogenase (IMPDH) catalyzes the rate-limiting step in the de novo GTP biosynthetic pathway and plays essential roles in cell proliferation. As a clinical target, IMPDH has been studied for decades, but it has only been within the last years that we are starting to understand the complexity of the mechanisms of its physiological regulation. Here, we report structural and functional insights into how adenine and guanine nucleotides control a conformational switch that modulates the assembly of the two human IMPDH enzymes into cytoophidia and allosterically regulates their catalytic activity. In vitro reconstituted micron-length cytoophidia-like structures show catalytic activity comparable to unassembled IMPDH but, in turn, are more resistant to GTP/GDP allosteric inhibition. Therefore, IMPDH cytoophidia formation facilitates the accumulation of high levels of guanine nucleotides when the cell requires it. Finally, we demonstrate that most of the IMPDH retinopathy-associated mutations abrogate GTP/GDP-induced allosteric inhibition and alter cytoophidia dynamics., This work was supported by the Spanish Ministerio de Ciencia, Innovación y Universidades (grants BFU2016-79237-P to R.M.B. and BIO2014-56930-P to J.L.R.)., Peer reviewed